2010年自身免疫性肝病临床进展回顾(2)

clinical practice guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267.

[4] Shi J, Li Z, Zeng X, et al. Ursodeoxycholic acid in primary

sclerosing cholangitis:meta-analysis of randomized controlled trials[J]. Hepatol Res, 2009, 39(9): 865-873.

[5] Sinakos E, Marschall HU, Lindor K, et al. Bile acid changes after

high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression[J]. Hepatology,

569

2010, 52(1): 197-203.

[6] Barngarulingam SY, Bjornsson E, Enders F, et al. Long term

outcomes of positive fluorescence in situ hybridization (FISH) tests in primary sclerosing cholangitis[J]. Hepatology, 2010, 51(1): 174-180.

[7] Chapman WC. Fluorescent in situ hybridization testing in primary

sclerosing cholangitis: useful testing or a random chance result?[J]. Hepatology, 2010, 51(1): 16-19.

[8] Kaplan MM, Bonder A, Ruthazer R, et al. Methotrexate in

patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J]. Dig Dis Sci, 2010, 55(11): 3207-3217.

[9] Rabahi N, Chrétien Y, Gaouar F, et al. Triple therapy with

ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J]. Gastroenterol Clin Biol, 2010, 34(4-5): 283-287.

[10] Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate

for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J]. Aliment Pharmacol Ther, 2011, 33(2): 235-342.

[11] Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary

cirrhosis following incomplete response to ursodeoxycholic acid[J]. J Clin Gastroenterol, 2010, 44(5): 371-373.

[12] Silveira MG, Brunt EM, Heathcote J, et al. American Association

for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis[J]. Hepatology, 2010, 52(1): 349-359.

[13] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and

management of autoimmune hepatitis[J]. Hepatology, 2010, 51(6): 2193-2213.

[14] Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced

autoimmune hepatitis: clinical characteristics and prognosis[J]. Hepatology, 2010, 51(6): 2040-2048.

[15] Umemura T, Zen Y, Hamano H, et al. IgG4 associated autoimmune

hepatitis: a differential diagnosis for classical autoimmune hepatitis[J]. Gut, 2007, 56(10): 1471-1472.

[16] Chung H, Watanabe T, Kudo M, et al. Identification and

characterization of IgG4-associated autoimmune hepatitis[J]. Liver Int, 2010, 30(2): 222-231.

[17] Umemura T, Zen Y, Hamano H, et al. Clinical significance of

immunoglobulin G4-associated autoimmune hepatitis[J]. J Gastroenterol, 2011, 46(Suppl 1): 48-55.

[18] Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap

syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385.

(本文编辑:王 莹)